WO2017113475A1 - Traditional chinese medicine composition for treating gastritis - Google Patents

Traditional chinese medicine composition for treating gastritis Download PDF

Info

Publication number
WO2017113475A1
WO2017113475A1 PCT/CN2016/073421 CN2016073421W WO2017113475A1 WO 2017113475 A1 WO2017113475 A1 WO 2017113475A1 CN 2016073421 W CN2016073421 W CN 2016073421W WO 2017113475 A1 WO2017113475 A1 WO 2017113475A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
traditional chinese
chinese medicine
medicine composition
Prior art date
Application number
PCT/CN2016/073421
Other languages
French (fr)
Chinese (zh)
Inventor
陈致慜
马靖喧
李春雷
霍志金
Original Assignee
邯郸制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 邯郸制药股份有限公司 filed Critical 邯郸制药股份有限公司
Publication of WO2017113475A1 publication Critical patent/WO2017113475A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967—Lilium, e.g. tiger lily or Easter lily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Definitions

  • the invention relates to a preparation method of a traditional Chinese medicine composition, in particular to a preparation method of a traditional Chinese medicine composition for treating gastritis and a pharmaceutical preparation prepared by the method.
  • Morodan is a drug that reduces the stomach, reduces spleen and swells, and relieves pain. For chronic atrophic gastritis and stomach pain, fullness, nausea, poor appetite, belching, heartburn and other symptoms. Dosage, oral, honey pill once 9 ⁇ 18g, 3 times a day, with rice soup or warm water before meals, or as directed.
  • Angelica has inhibitory effects on dysentery bacillus, Vibrio cholerae, Proteus and Escherichia coli.
  • Panax notoginseng saponins have strong inhibitory effects on certain fungi.
  • Atractylodes can effectively improve the humoral immune function in addition to the spleen.
  • the atractylodes are fried with bran, the eucalyptus is treated with vinegar, and the chicken is made of fried chicken.
  • Chinese patent 200710120838.4 discloses the following method for determining the content of Morodan.
  • the content is determined as follows:
  • Chromatographic conditions and system suitability test using octadecylsilane bonded silica as a filler; 15-60:40-85 acetonitrile-water as mobile phase; detection wavelength is 230nm, theoretical plate number calculated according to paeoniflorin peak Should not be less than 1000 ⁇ 5000;
  • Preparation of reference solution accurately weigh the appropriate amount of paeoniflorin reference substance, add methanol, ethanol, n-butanol, water, chloroform or ethyl acetate to make a solution containing 30-50 ⁇ g parts per 1ml, that is;
  • Preparation of the test solution Take the Morodan Xiaomi Pill or the big honey pill under the weight difference, cut it, accurately weigh 1 ⁇ 10g, add diatomaceous earth 1 ⁇ 10g, stir it evenly, set the plug In the bottle, precisely add solvent methanol, ethanol, n-butanol, water, chloroform or ethyl acetate 15-25ml, concealed, weighed, sonicated or hot reflux or cold soak extraction for 30 minutes, removed and placed at room temperature After weighing, use solvent methanol, ethanol, n-butanol, water, chloroform or ethyl acetate to make up to 15-25ml, shake, filter, precision draw 4-6ml of continuous filtrate, set 10ml volumetric flask, add solvent Dilute to the mark with methanol, ethanol, n-butanol, water, chloroform or ethyl acetate, shake well, that is;
  • Determination method respectively, accurately draw the reference solution and the test solution 20 ⁇ l each, and inject it into the liquid chromatograph, and measure it, that is, the molarin should be not less than 1 part per part of the white peony with paeoniflorin C 23 H 28 O 11 0.8 mg portion.
  • the present invention provides a novel traditional Chinese medicine composition of Morodan, which is prepared from the following weight ratio traditional Chinese medicine raw materials.
  • the traditional Chinese medicine composition of the present invention is prepared from the following weight-matching traditional Chinese medicine raw materials.
  • the weight is calculated based on the crude drug.
  • the above composition is based on the weight. It can be increased or decreased according to the corresponding proportion during production. For example, mass production can be in kilograms or in tons. Scale production can also be in grams or milligrams, the weight can be increased or decreased, but the ratio of the weight ratio of raw herbs to the composition is unchanged.
  • the ratio of the above weight ratios is scientifically screened.
  • the proportion of the composition can be adjusted accordingly, increasing or decreasing by no more than 100%, and the efficacy is unchanged. .
  • the single-flavored traditional Chinese medicines in the above composition can also be replaced by appropriate traditional Chinese medicines having the same medicinal properties, and the traditional Chinese medicine preparations after replacement have the same drug action.
  • the traditional Chinese medicine composition of the present invention preferably in the form of a pharmaceutical preparation, is prepared by extracting or otherwise processing the traditional Chinese medicine raw material composed of the above formula to prepare a pharmaceutically active substance, and then using the substance as a raw material, and adding the medicine when necessary Accepted carriers are prepared according to conventional techniques of formulation.
  • the active substance may be obtained by separately extracting a traditional Chinese medicine raw material, or may be obtained by jointly extracting a traditional Chinese medicine raw material, or may be obtained by other methods, such as: crushing, pressing, calcining, grinding, sieving, seepage, extraction, water extraction, Alcohol extraction, ester extraction, Obtained by ketone extraction, chromatography, etc., and the active substances may be in the form of an extract, which may be a dry extract or a flow extract, and may be determined to have different concentrations depending on the needs of the preparation.
  • the pharmaceutically active substance in the traditional Chinese medicine composition of the present invention may be in a proportion of 0.1 to 99.9% by weight in the preparation, and the balance is a pharmaceutically acceptable carrier.
  • the pharmaceutical preparation may be present in a unit dosage form, which means a unit of the preparation, such as each tablet of the tablet, each capsule of the capsule, each bottle of the oral solution, granules per bag, and the like.
  • the traditional Chinese medicine preparation of the present invention may be any pharmaceutically acceptable dosage form, and the dosage forms include: tablets, capsules, granules, pills, powders, ointments, dandruffs, powders, solutions, injections, suppositories, sprays, drops , patch.
  • the preparation of the present invention is preferably an oral dosage form such as a capsule, a tablet, an oral solution, a granule, a pill, a powder, an agent, a paste or the like.
  • the preparation for oral administration may contain common excipients such as a binder, a filler, a diluent, a tablet, a lubricant, a disintegrant, a coloring agent, a flavoring agent and a wetting agent. .
  • Suitable fillers include cellulose, mannitol, lactose and other similar fillers.
  • Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulfate.
  • Solid oral compositions can be prepared by conventional methods such as mixing, filling, tableting, and the like. Repeated mixing allows the active material to be distributed throughout those compositions that use large amounts of filler.
  • the oral liquid preparation may be in the form of, for example, an aqueous or oily suspension, solution, emulsion, syrup or elixir, or may be a dry product which may be formulated with water or other suitable carrier before use.
  • Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel or hydrogenated edible fats.
  • Emulsifiers such as lecithin, sorbitan monooleate or gum arabic; non-aqueous vehicles (which may include edible oils), such as almond oil, fractionated coconut oil, oily esters of esters such as glycerol, propylene glycol or ethanol;
  • the agent for example, p-hydroxybenzyl or propylparaben or sorbic acid, and if desired, may contain conventional flavoring or coloring agents.
  • the traditional Chinese medicine preparation of the invention can be selectively added with a suitable pharmaceutically acceptable carrier when preparing the medicament, such as commonly used auxiliary ingredients: mannitol, sorbitol, sodium metabisulfite, sodium hydrogen sulfite, sodium thiosulfate, hydrochloric acid.
  • a suitable pharmaceutically acceptable carrier such as commonly used auxiliary ingredients: mannitol, sorbitol, sodium metabisulfite, sodium hydrogen sulfite, sodium thiosulfate, hydrochloric acid.
  • the preparation of the present invention is used according to the dosage at the time of use, and can be taken three times a day, 1-20 doses per time, such as: 1-20 bags or tablets or tablets.
  • the medicinal materials are boiled with water for 1-3 times, each time for 1.5-3 hours, and the decoction is combined, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content 60-80%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated, refrigerated by adding water, and filtered to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
  • the preparation method of the present invention has the following steps:
  • the herbs are boiled twice with water for 2 hours, combined with decoction, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content up to 70%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
  • the traditional Chinese medicine composition of the invention has the effects of preparing the stomach, reducing the spleen and swelling, and relieving the pain of the collaterals, treating the gastritis and stomach pain, swelling, nausea, stagnation, suffocation, heartburn and the like. Application in .
  • a preferred preparation of the present invention is a concentrated pellet, which is prepared by taking a medicinal active ingredient, a pulverized powder, and adding 0.6-1.5 parts by weight of refined honey per 1 part by weight to prepare a concentrated honey pellet.
  • the invention improves the formula, removes the adjuvant medicinal sputum, and makes the medicine 9 scutellaria sinensis 2 medicinal herbs, the mantle: cooling blood to stop bleeding, detoxification and sore; nine jasmine: open phlegm, Rescuing your spleen
  • the traditional Sanweijun medicine is replaced with rehmannia root, asparagus, and Dendrobium.
  • Ophiopogon japonicus and asparagus have moisturizing lung and nourishing yin; Dendrobium and Dendrobium candidum are beneficial to stomach and nourishing yin and clearing heat; Xuan participates in rehmannia: clearing heat and cooling blood.
  • the method of the invention obviously increases the main active ingredient, the drug effect is obviously improved, and the stability of the preparation is obviously improved.
  • mice were administered in groups. On the 7th day after administration, the animals in each group were fasted for 48 hours. Before the test, the animals in each group were re-administered (water) once. After 2 hours, each rat was intragastrically administered with 2 ml of acidic ethanol (150 mmol). /L hydrochloric acid and 60% ethanol were mixed in a ratio of 1:1). After 1 hour, the rats were anesthetized with an excess of ether, and the rats were sacrificed. The stomach was removed by abdomen. The cardia was clamped with a clip, and 5 ml of 1% formaldehyde solution was injected from the pylorus to clamp the pylorus.
  • the whole stomach was fixed in 1% formaldehyde solution for 10 min, cut along the stomach, the stomach was turned out, the contents were gently washed away with water, the stomach was spread on a glass plate, and the gastric mucosal damage was measured with a precision caliper.
  • the length is calculated as the gastric mucosal injury index by the sum of the length of the injury (the doubling of the damage width is greater than 1 mm), and the inhibition rate is calculated.
  • Animals were administered in groups of 10 rats. After the last administration, the animals in each group were fasted for 24 hours, anesthetized with ether, cut a small mouth along the midline of the abdomen, gently pulled out the stomach, ligated the pylorus, and then 12
  • the intestinal administration was performed once, and the abdominal wall incision was sutured. After 6 hours, the incision was opened and the cardia was ligated, the whole stomach was removed, the blood was removed by filter paper, the stomach wall was cut along the stomach, and the stomach contents were decanted and collected in a graduated centrifuge tube. Centrifuge at 1500r/min for 10min, accurately record the amount of gastric juice, determine the total acidity of gastric juice with phenol red as indicator, and measure the activity of pepsin by Mettle capillary method.
  • Both the present invention group and the prior art group can reduce the number of deaths of S. aureus infected mice and prolong the survival days of infected mice;
  • Both the present invention group and the prior art group can reduce the degree of swelling of the auricle caused by xylene in mice.
  • the dosage of the drug is lowered, the content of the active ingredient is increased, the stability of the preparation is improved, and the efficacy of the drug is improved.
  • the herbs are boiled twice with water for 2 hours, combined with decoction, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content up to 70%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
  • the medicinal materials are boiled for 1 time, 1.5 hours each time, and the decoction is combined, filtered, and the filtrate is concentrated to an appropriate amount.
  • Ethanol is added to make the alcohol content 60%, allowed to stand, filtered, and the ethanol is recovered, and the filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
  • the medicinal materials are boiled for 3 times with water for 3 hours, combined with decoction, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content 80%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
  • Example 1 The pharmaceutically active substance obtained in Example 1 was prepared by a conventional preparation preparation method.
  • the pharmaceutically active substance obtained in Example 1 was prepared into a tablet by a conventional preparation preparation method.
  • Example 1 Taking the pharmaceutically active substance obtained in Example 1 and preparing a pellet by a conventional preparation preparation method
  • the pharmaceutically active substance obtained in Example 1 was prepared into a granule by a conventional preparation preparation method.
  • the pharmaceutically active substance obtained in Example 1 was prepared into an oral liquid preparation by a conventional preparation preparation method.
  • the pharmaceutically active substance obtained in Example 1 was prepared into a pill by a conventional preparation preparation method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A traditional Chinese medicine composition for treating gastritis, comprising the following crude drugs: 30-80 parts by weight of Bulbus lilii, 30-80 parts by weight of Poria, 40-90 parts by weight of Radix rehmanniae, 30-80 parts by weight of Radix chuanxiong, 5-30 parts by weight of Endothelium corneum gigeriae galli, 30-70 parts by weight of Radix linderae, 20-60 parts by weight of Rhizoma alismatis, 50-90 parts by weight of Radix asparagi, 5-30 parts by weight of Radix notoginseng, 10-50 parts by weight of Rhizoma atractylodis macrocephalae, 20-60 parts by weight of Radix angelicae sinensis, 30-80 parts by weight of Herba artemisiae scopariae, 50-90 parts by weight of Radix sanguisorbae, 20-60 parts by weight of Pollen typhae, 30-80 parts by weight of Rhizoma corydalis, 120-180 parts by weight of Radix paeoniae alba, 40-90 parts by weight of Dendrobium officinale, and 20-60 parts by weight of Rhizoma anemones altaicae.

Description

一种治疗胃炎的中药组合物Traditional Chinese medicine composition for treating gastritis 发明领域Field of invention
本发明涉及一种中药组合物的制备方法，特别涉及用于治疗胃炎的中药组合物的制备方法以及用该方法制备的药物制剂。The invention relates to a preparation method of a traditional Chinese medicine composition, in particular to a preparation method of a traditional Chinese medicine composition for treating gastritis and a pharmaceutical preparation prepared by the method.
背景技术Background technique
摩罗丹是一种和胃降逆，健脾消胀，通络定痛的药物。用于慢性萎缩性胃炎及胃疼，胀满，痞闷，纳呆，嗳气，烧心等症。用法用量，口服，蜜丸一次9～18g份，一日3次，饭前用米汤或温开水送下，或遵医嘱。其由百合、麦冬、石斛、茯苓、白术(麸炒)、乌药、白芍、三七、延胡索(醋炙)、鸡内金(炒香)、玄参、当归等18味中药制备而成，药理作用如下Morodan is a drug that reduces the stomach, reduces spleen and swells, and relieves pain. For chronic atrophic gastritis and stomach pain, fullness, nausea, poor appetite, belching, heartburn and other symptoms. Dosage, oral, honey pill once 9 ~ 18g, 3 times a day, with rice soup or warm water before meals, or as directed. It is prepared from 18 kinds of traditional Chinese medicines such as Lily, Ophiopogon japonicus, Dendrobium, Poria, Atractylodes Rhizome, Brassica oleracea L., Radix Paeoniae Alba, Radix Notoginseng, Yanhusuo (Vinegar), Chicken Inner Gold (Sautéed), Scrophulariaceae and Angelica. Cheng, pharmacological effects are as follows
1 作用：当归对痢疾杆菌、霍乱弧菌、变形杆菌、大肠杆菌均有抑制作用，三七总皂甙对某些真菌有较强抑制作用。1 Function: Angelica has inhibitory effects on dysentery bacillus, Vibrio cholerae, Proteus and Escherichia coli. Panax notoginseng saponins have strong inhibitory effects on certain fungi.
2 胃粘膜：本方对胃粘膜损伤有修复作用。2 gastric mucosa: This side has a repair effect on gastric mucosal damage.
3 药理研究乌药对胃肠道平滑肌有兴奋和抑制的双向调节作用，促进消化液分泌；鸡内金提高胃液分泌量，酸度和消化能力。3 Pharmacological studies Uygur medicine has two-way regulation of excitability and inhibition of gastrointestinal smooth muscle, promoting the secretion of digestive juice; chicken gold increases gastric secretion, acidity and digestion.
4 免疫功能：据药理性实验茯苓、白术除健脾外，还可有效提高体液免疫功能。4 Immune function: According to the pharmacological experiment, Atractylodes can effectively improve the humoral immune function in addition to the spleen.
5 药理发现本方中三七、当归、茯苓等皆有护肝、解除酒精肝中毒，促进肝中血清转化的功能。 5 Pharmacology found that the party's Sanqi, Angelica, sputum, etc. have liver protection, relieve alcoholic liver poisoning, and promote the function of seroconversion in the liver.
中国专利公开了摩罗丹制剂的以下配方The Chinese patent discloses the following formulation of the formulation of Morodan
Figure PCTCN2016073421-appb-000001
Figure PCTCN2016073421-appb-000001
所述白术用麸炒，延胡索用醋炙，鸡内金选用炒鸡内金。The atractylodes are fried with bran, the eucalyptus is treated with vinegar, and the chicken is made of fried chicken.
以及制备方法：And preparation method:
以上十八味，加水煎煮1-3次，每次1.5-3小时，合并煎液，滤过，滤液浓缩至适量，加入乙醇，使含醇量达60-80％，静置，滤过，回收乙醇，滤液浓缩，加水冷藏，滤过，最后经过常规工序直接或加入药学上可接受的赋型剂制成临床可接受的剂型。The above eighteen flavors, add water 1-3 times, each time 1.5-3 hours, combine the decoction, filter, the filtrate is concentrated to the appropriate amount, add ethanol, so that the alcohol content reaches 60-80%, let stand, filter The ethanol is recovered, the filtrate is concentrated, refrigerated with water, filtered, and finally a clinically acceptable dosage form is prepared by a conventional procedure directly or by adding a pharmaceutically acceptable excipient.
中国专利200710120838.4公开了摩罗丹以下含量测定方法，Chinese patent 200710120838.4 discloses the following method for determining the content of Morodan.
含量测定如下：The content is determined as follows:
照高效液相色谱法测定；Determined by high performance liquid chromatography;
色谱条件与系统适应性试验：用十八烷基硅烷键合硅胶为填充剂；以15-60:40-85的乙腈-水为流动相；检测波长为230nm，理论板数按芍药苷峰计算应不低于1000～5000；Chromatographic conditions and system suitability test: using octadecylsilane bonded silica as a filler; 15-60:40-85 acetonitrile-water as mobile phase; detection wavelength is 230nm, theoretical plate number calculated according to paeoniflorin peak Should not be less than 1000 ~ 5000;
对照品溶液的制备：精密称取芍药苷对照品适量，加溶剂甲醇、乙醇、正丁醇、水、三氯甲烷或乙酸乙酯制成每1ml含30-50μg份的溶液，即得； Preparation of reference solution: accurately weigh the appropriate amount of paeoniflorin reference substance, add methanol, ethanol, n-butanol, water, chloroform or ethyl acetate to make a solution containing 30-50μg parts per 1ml, that is;
供试品溶液的制备：取摩罗丹小蜜丸或重量差异项下的大蜜丸，剪碎，精密称取1～10g份，加入硅藻土1～10g份，研匀，置具塞锥形瓶中，精密加入溶剂甲醇、乙醇、正丁醇、水、三氯甲烷或乙酸乙酯15-25ml，密塞，称重，超声处理或热回流或冷浸提取30分钟，取出放至室温后称重，用溶剂甲醇、乙醇、正丁醇、水、三氯甲烷或乙酸乙酯补足至15-25ml摇匀，滤过，精密吸取续滤液4-6ml，置10ml量瓶中，加溶剂甲醇、乙醇、正丁醇、水、三氯甲烷或乙酸乙酯稀释至刻度，摇匀，即得；Preparation of the test solution: Take the Morodan Xiaomi Pill or the big honey pill under the weight difference, cut it, accurately weigh 1~10g, add diatomaceous earth 1~10g, stir it evenly, set the plug In the bottle, precisely add solvent methanol, ethanol, n-butanol, water, chloroform or ethyl acetate 15-25ml, concealed, weighed, sonicated or hot reflux or cold soak extraction for 30 minutes, removed and placed at room temperature After weighing, use solvent methanol, ethanol, n-butanol, water, chloroform or ethyl acetate to make up to 15-25ml, shake, filter, precision draw 4-6ml of continuous filtrate, set 10ml volumetric flask, add solvent Dilute to the mark with methanol, ethanol, n-butanol, water, chloroform or ethyl acetate, shake well, that is;
测定法：分别精密吸取对照品溶液与供试品溶液各20μl，注入液相色谱仪，测定，即得；摩罗丹每1g份含白芍以芍药苷C23H28O11计，不得少于0.8mg份。Determination method: respectively, accurately draw the reference solution and the test solution 20μl each, and inject it into the liquid chromatograph, and measure it, that is, the molarin should be not less than 1 part per part of the white peony with paeoniflorin C 23 H 28 O 11 0.8 mg portion.
本发明人在临床和生产实践中发现，现有技术在疗效，稳定性，有效成分含量，药物的使用量等方面需要改进，为此本发明人对现有技术进行了改进，从而完成了本发明。The present inventors have found in clinical and production practice that the prior art needs improvement in terms of efficacy, stability, content of active ingredients, amount of drug used, etc., for which the inventors have improved the prior art, thereby completing the present invention. invention.
发明内容：Summary of the invention:
为改进现有技术的缺陷，本发明提供一种摩罗丹的新的中药组合物，所述中药组合物由以下重量配比的中药原料药制备而成，In order to improve the defects of the prior art, the present invention provides a novel traditional Chinese medicine composition of Morodan, which is prepared from the following weight ratio traditional Chinese medicine raw materials.
百合30-80重量份、茯苓30-80重量份、生地黄40-90重量份、川芎30-80重量份、鸡内金5-30重量份、乌药30-70重量份、泽泻20-60重量份、天冬50-90重量份、三七5-30重量份、白术10-50重量份、当归20-60重量份、茵陈30-80重量份、地榆50-90重量份、蒲黄20-60重量份、延胡索30-80重量份、白芍120-180重量份、铁皮石 斛40-90重量份、九节菖蒲20-60重量份优选的，本发明所述的中药组合物，由以下重量配比的中药原料药制备而成，Lily 30-80 parts by weight, 茯苓30-80 parts by weight, rehmannia 40-90 parts by weight, Chuanxiong 30-80 parts by weight, chicken inner gold 5-30 parts by weight, black peony 30-70 parts by weight, Alisma 20- 60 parts by weight, 50-90 parts by weight of aspart, 5-30 parts by weight of triplicate, 10-50 parts by weight of Atractylodes, 20-60 parts by weight of Angelica sinensis, 30-80 parts by weight of mersolic, 50-90 parts by weight of mantle, 20-60 parts by weight of Puhuang, 30-80 parts by weight of Corydalis, 120-180 parts by weight of white peony, Dendrite 斛40-90 parts by weight, 20-60 parts by weight of the nine-legged calamus, preferably, the traditional Chinese medicine composition of the present invention is prepared from the following weight-matching traditional Chinese medicine raw materials.
百合60重量份、茯苓60重量份、生地黄65重量份、川芎55重量份、鸡内金15重量份、乌药45重量份、泽泻45重量份、天冬75重量份、三七15重量份、白术30重量份、当归45重量份、茵陈60重量份、地榆75重量份、蒲黄45重量份、延胡索60重量份、白芍150重量份、铁皮石斛75重量份、九节菖蒲45重量份60 parts by weight of lily, 60 parts by weight of glutinous rice, 65 parts by weight of rehmannia glutinosa, 55 parts by weight of Chuanxiong, 15 parts by weight of chicken gold, 45 parts by weight of black peony, 45 parts by weight of Alisma, 75 parts by weight of aspart, and weight of 37. , 30 parts by weight of Atractylodes Rhizome, 45 parts by weight of Angelica sinensis, 60 parts by weight of Yinchen, 75 parts by weight of mantle, 45 parts by weight of Puhuang, 60 parts by weight of Corydalis, 150 parts by weight of Radix, 75 parts by weight of Dendrobium Dendrobium, and 9 45 parts by weight
以上组成中，重量是以生药计算的，以上组成是按重量作为配比的，在生产时可按照相应比例增大或减少，如大规模生产可以以公斤为单位，或以吨为单位，小规模生产也可以以克或毫克为单位，重量可以增大或者减小，但各组成之间的生药材重量配比的比例不变。In the above composition, the weight is calculated based on the crude drug. The above composition is based on the weight. It can be increased or decreased according to the corresponding proportion during production. For example, mass production can be in kilograms or in tons. Scale production can also be in grams or milligrams, the weight can be increased or decreased, but the ratio of the weight ratio of raw herbs to the composition is unchanged.
以上重量配比的比例是经过科学筛选得到的，对于特殊情况，如重症或轻症，肥胖或瘦小的，可以相应调整组成的量的配比，增加或减少不超过100％，药效不变。The ratio of the above weight ratios is scientifically screened. For special cases, such as severe or mild disease, obesity or thinness, the proportion of the composition can be adjusted accordingly, increasing or decreasing by no more than 100%, and the efficacy is unchanged. .
以上组成中的单味中药，尤其是臣药和佐药，也可以被适当的具有相同药性的中药替换，替换后的中药制剂其药物作用不变。The single-flavored traditional Chinese medicines in the above composition, especially the medicinal herbs and adjuvants, can also be replaced by appropriate traditional Chinese medicines having the same medicinal properties, and the traditional Chinese medicine preparations after replacement have the same drug action.
本发明的中药组合物，最佳是药物制剂的形式，是通过将上述配方组成的中药原料经过提取或其他方式加工，制成药物活性物质，随后，以该物质为原料，需要时加入药物可接受的载体，按照制剂学的常规技术制成的。所述活性物质可以通过分别提取中药原料得到，也可以通过共同提取中药原料得到，也可以通过其他方式得到，如：通过粉碎、压榨、煅烧、研磨、过筛、渗漉、萃取、水提、醇提、酯提、 酮提、层析等方法得到、这些活性物质可以是浸膏形式的物质，可以是干浸膏也可以是流浸膏，根据制剂的不同需要决定制成不同的浓度。The traditional Chinese medicine composition of the present invention, preferably in the form of a pharmaceutical preparation, is prepared by extracting or otherwise processing the traditional Chinese medicine raw material composed of the above formula to prepare a pharmaceutically active substance, and then using the substance as a raw material, and adding the medicine when necessary Accepted carriers are prepared according to conventional techniques of formulation. The active substance may be obtained by separately extracting a traditional Chinese medicine raw material, or may be obtained by jointly extracting a traditional Chinese medicine raw material, or may be obtained by other methods, such as: crushing, pressing, calcining, grinding, sieving, seepage, extraction, water extraction, Alcohol extraction, ester extraction, Obtained by ketone extraction, chromatography, etc., and the active substances may be in the form of an extract, which may be a dry extract or a flow extract, and may be determined to have different concentrations depending on the needs of the preparation.
本发明的中药组合物中的药物活性物质，其在制剂中所占重量百分比可以是0.1-99.9％，其余为药物可接受的载体。作为药物制剂，可以以单位剂量形式存在，所述单位剂量形式是指制剂的单位，如片剂的每片，胶囊的每粒胶囊，口服液的每瓶，颗粒剂每袋等。The pharmaceutically active substance in the traditional Chinese medicine composition of the present invention may be in a proportion of 0.1 to 99.9% by weight in the preparation, and the balance is a pharmaceutically acceptable carrier. The pharmaceutical preparation may be present in a unit dosage form, which means a unit of the preparation, such as each tablet of the tablet, each capsule of the capsule, each bottle of the oral solution, granules per bag, and the like.
本发明的中药制剂可以是任何可药用的剂型，这些剂型包括：片剂、胶囊剂、颗粒剂、丸剂、散剂、膏剂、丹剂、粉剂、溶液剂、注射剂、栓剂、喷雾剂、滴剂、贴剂。本发明的制剂，优选的是口服剂型，如：胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂等。The traditional Chinese medicine preparation of the present invention may be any pharmaceutically acceptable dosage form, and the dosage forms include: tablets, capsules, granules, pills, powders, ointments, dandruffs, powders, solutions, injections, suppositories, sprays, drops , patch. The preparation of the present invention is preferably an oral dosage form such as a capsule, a tablet, an oral solution, a granule, a pill, a powder, an agent, a paste or the like.
本发明的中药制剂，其口服给药的制剂可含有常用的赋形剂，诸如粘合剂、填充剂、稀释剂、压片剂、润滑剂、崩解剂、着色剂、调味剂和湿润剂。The traditional Chinese medicine preparation of the present invention, the preparation for oral administration may contain common excipients such as a binder, a filler, a diluent, a tablet, a lubricant, a disintegrant, a coloring agent, a flavoring agent and a wetting agent. .
适用的填充剂包括纤维素、甘露糖醇、乳糖和其它类似的填充剂。适宜的崩解剂包括淀粉、聚乙烯吡咯烷酮和淀粉衍生物，例如羟基乙酸淀粉钠。适宜的润滑剂包括，例如硬脂酸镁。适宜的药物可接受的湿润剂包括十二烷基硫酸钠。Suitable fillers include cellulose, mannitol, lactose and other similar fillers. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycolate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulfate.
可通过混合，填充，压片等常用的方法制备固体口服组合物。进行反复混合可使活性物质分布在整个使用大量填充剂的那些组合物中。 Solid oral compositions can be prepared by conventional methods such as mixing, filling, tableting, and the like. Repeated mixing allows the active material to be distributed throughout those compositions that use large amounts of filler.
口服液体制剂的形式例如可以是水性或油性悬浮液、溶液、乳剂、糖浆剂或酏剂，或者可以是一种在使用前可用水或其它适宜的载体复配的干燥产品。这种液体制剂可含有常规的添加剂，诸如悬浮剂，例如山梨醇、糖浆、甲基纤维素、明胶、羟乙基纤维素、羧甲基纤维素、硬脂酸铝凝胶或氢化食用脂肪，乳化剂，例如卵磷脂、脱水山梨醇一油酸酯或阿拉伯胶；非水性载体(它们可以包括食用油)，例如杏仁油、分馏椰子油、诸如甘油的酯的油性酯、丙二醇或乙醇；防腐剂，例如对羟基苯甲酯或对羟基苯甲酸丙酯或山梨酸，并且如果需要，可含有常规的香味剂或着色剂。The oral liquid preparation may be in the form of, for example, an aqueous or oily suspension, solution, emulsion, syrup or elixir, or may be a dry product which may be formulated with water or other suitable carrier before use. Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel or hydrogenated edible fats. Emulsifiers such as lecithin, sorbitan monooleate or gum arabic; non-aqueous vehicles (which may include edible oils), such as almond oil, fractionated coconut oil, oily esters of esters such as glycerol, propylene glycol or ethanol; The agent, for example, p-hydroxybenzyl or propylparaben or sorbic acid, and if desired, may contain conventional flavoring or coloring agents.
本发明的中药制剂，在制备成药剂时可选择性的加入适合的药物可接受的载体，如常用的辅料成分：甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β－环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。The traditional Chinese medicine preparation of the invention can be selectively added with a suitable pharmaceutically acceptable carrier when preparing the medicament, such as commonly used auxiliary ingredients: mannitol, sorbitol, sodium metabisulfite, sodium hydrogen sulfite, sodium thiosulfate, hydrochloric acid. Cysteine, thioglycolic acid, methionine, vitamin C, disodium EDTA, calcium EDTA, monovalent alkali metal carbonate, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, Sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and its derivatives, alginate , gelatin, polyvinylpyrrolidone, glycerin, soil temperature 80, agar, calcium carbonate, calcium hydrogencarbonate, surfactant, polyethylene glycol, cyclodextrin, β-cyclodextrin, phospholipid materials, kaolin, talcum powder, Calcium stearate, magnesium stearate, and the like.
本发明的制剂在使用时根据况确定用法用量，可每日服三次，每次1-20剂，如：1-20袋或粒或片。The preparation of the present invention is used according to the dosage at the time of use, and can be taken three times a day, 1-20 doses per time, such as: 1-20 bags or tablets or tablets.
本发明所述的中药组合物，优选的制备方法，步骤如下： The traditional Chinese medicine composition of the present invention, the preferred preparation method, the steps are as follows:
药材加水煎煮1-3次，每次1.5-3小时，合并煎液，滤过，滤液浓缩至适量，加入乙醇，使含醇量达60-80％，静置，滤过，回收乙醇，滤液浓缩，加水冷藏，滤过，得到药物活性物质，经过制剂方法，制备成药物制剂组合物。The medicinal materials are boiled with water for 1-3 times, each time for 1.5-3 hours, and the decoction is combined, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content 60-80%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated, refrigerated by adding water, and filtered to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
最优选的，本发明所述的制备方法，步骤如下：Most preferably, the preparation method of the present invention has the following steps:
药材加水煎煮2次，每次2小时，合并煎液，滤过，滤液浓缩至适量，加入乙醇，使含醇量达70％，静置，滤过，回收乙醇，滤液浓缩，加水冷藏，滤过，得到药物活性物质，经过制剂方法，制备成药物制剂组合物。The herbs are boiled twice with water for 2 hours, combined with decoction, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content up to 70%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
本发明所述的中药组合物在制备具有和胃降逆，健脾消胀，通络定痛之功效，治疗胃炎及胃疼，胀满，痞闷，纳呆，嗳气，烧心等症的药物中的应用。The traditional Chinese medicine composition of the invention has the effects of preparing the stomach, reducing the spleen and swelling, and relieving the pain of the collaterals, treating the gastritis and stomach pain, swelling, nausea, stagnation, suffocation, heartburn and the like. Application in .
本发明优选的制剂为浓缩丸，其制备方法如下，取药物活性成分、粉碎后药粉每1重量份加0.6-1.5重量份炼蜜制成浓缩蜜丸。A preferred preparation of the present invention is a concentrated pellet, which is prepared by taking a medicinal active ingredient, a pulverized powder, and adding 0.6-1.5 parts by weight of refined honey per 1 part by weight to prepare a concentrated honey pellet.
本发明在现有技术的基础上，对配方进行了改进，去掉佐药地榆、使药九节菖蒲2味药，地榆：凉血止血，解毒敛疮；九节菖蒲：开窍化痰，醒脾安神。On the basis of the prior art, the invention improves the formula, removes the adjuvant medicinal sputum, and makes the medicine 9 scutellaria sinensis 2 medicinal herbs, the mantle: cooling blood to stop bleeding, detoxification and sore; nine jasmine: open phlegm, Rescuing your spleen
本发明中，用生地黄、天冬、铁皮石斛替换现有技术中的三味君药。麦冬与天冬具有润肺养阴；石斛与铁皮石斛具有益胃生津，滋阴清热；玄参与地黄：清热凉血。In the present invention, the traditional Sanweijun medicine is replaced with rehmannia root, asparagus, and Dendrobium. Ophiopogon japonicus and asparagus have moisturizing lung and nourishing yin; Dendrobium and Dendrobium candidum are beneficial to stomach and nourishing yin and clearing heat; Xuan participates in rehmannia: clearing heat and cooling blood.
本发明的方法和现有技术相比，主要活性成分明显增加，药效明显提高，制剂稳定性明显提高， Compared with the prior art, the method of the invention obviously increases the main active ingredient, the drug effect is obviously improved, and the stability of the preparation is obviously improved.
以下通过实验数据说明本发明的有益效果：The beneficial effects of the present invention are illustrated below by experimental data:
实验内容：Experimental content:
本发明和现有技术进行对比实验Comparative experiment between the present invention and prior art
实验1、对酸性乙醇致大鼠急性胃黏膜损伤的影响Experiment 1, the effect of acid ethanol on acute gastric mucosal injury in rats
动物分组给药，于给药第7天各组动物分别禁食不禁水48h，试验前各组动物再灌胃给药(水)1次，2h后每只大鼠灌胃酸性乙醇2ml(150mmol/L盐酸与60％乙醇按1∶1比例混合)，1h后分别用过量乙醚麻醉大鼠致死，开腹取胃，用夹子夹紧贲门，由幽门注入1％甲醛溶液5ml，夹紧幽门，将全胃置于1％甲醛溶液中固定10min，沿胃大弯剪开，将胃外翻，用清水轻轻洗去内容物，将胃平铺于玻璃板上，用精密卡尺测量胃黏膜损伤长度，以损伤长度(损伤宽度大于1mm者加倍计算)总和作为胃黏膜损伤指数，并计算抑制率。Animals were administered in groups. On the 7th day after administration, the animals in each group were fasted for 48 hours. Before the test, the animals in each group were re-administered (water) once. After 2 hours, each rat was intragastrically administered with 2 ml of acidic ethanol (150 mmol). /L hydrochloric acid and 60% ethanol were mixed in a ratio of 1:1). After 1 hour, the rats were anesthetized with an excess of ether, and the rats were sacrificed. The stomach was removed by abdomen. The cardia was clamped with a clip, and 5 ml of 1% formaldehyde solution was injected from the pylorus to clamp the pylorus. The whole stomach was fixed in 1% formaldehyde solution for 10 min, cut along the stomach, the stomach was turned out, the contents were gently washed away with water, the stomach was spread on a glass plate, and the gastric mucosal damage was measured with a precision caliper. The length is calculated as the gastric mucosal injury index by the sum of the length of the injury (the doubling of the damage width is greater than 1 mm), and the inhibition rate is calculated.
实验结果如下：The experimental results are as follows:
从结果可见，各组大鼠胃黏膜均有不同程度损伤，本发明组和现有技术组均较模型对照组轻，损伤指数明显降低(P<0.05)。It can be seen from the results that the gastric mucosa of each group had different degrees of damage. The present invention group and the prior art group were lighter than the model control group, and the injury index was significantly decreased (P<0.05).
大鼠再生粘膜厚度的比较Comparison of rat regenerative mucosal thickness
组别Group 动物数(只)Number of animals (only) 再生粘膜厚度(μm)Regenerated mucosal thickness (μm)
对照组Control group 1010 419419
模型组Model group 1010 9999
本发明组Group of the invention 1010 344344
现有技术组Existing technology group 1010 299299
溃疡灶肉芽瘢痕层厚度的比较 Comparison of thickness of granulation scar layer in ulcerated stove
组别Group 动物数(只)Number of animals (only) 肉芽瘢痕层厚度(μm)Granulation scar thickness (μm)
对照组Control group 1010 00
模型组Model group 1010 0.590.59
本发明组Group of the invention 1010 0.150.15
现有技术组Existing technology group 1010 0.230.23
实验2、对大鼠胃液分泌的影响Experiment 2, the effect on gastric juice secretion in rats
动物分组给药，每组10只大鼠，末次给药后各组动物分别禁食禁水24h，用乙醚麻醉，沿腹中线剪开小口，轻轻拉出胃，结扎幽门，再由十二指肠给药1次，缝合腹壁切口，6h后拆线开腹结扎贲门，摘除全胃，用滤纸擦净血迹，沿胃大弯剪开胃壁，倾出胃内容物，收集于刻度离心管中，以1500r/min速度离心10min，精确记录胃液量，以酚红为指示剂测定胃液总酸度，采用麦特毛细管法测定胃蛋白酶活性。Animals were administered in groups of 10 rats. After the last administration, the animals in each group were fasted for 24 hours, anesthetized with ether, cut a small mouth along the midline of the abdomen, gently pulled out the stomach, ligated the pylorus, and then 12 The intestinal administration was performed once, and the abdominal wall incision was sutured. After 6 hours, the incision was opened and the cardia was ligated, the whole stomach was removed, the blood was removed by filter paper, the stomach wall was cut along the stomach, and the stomach contents were decanted and collected in a graduated centrifuge tube. Centrifuge at 1500r/min for 10min, accurately record the amount of gastric juice, determine the total acidity of gastric juice with phenol red as indicator, and measure the activity of pepsin by Mettle capillary method.
实验结果如下：The experimental results are as follows:
从结果可见，本发明组和现有技术组均可降低胃液总酸度及胃蛋白酶活性(P>0.05)。It can be seen from the results that both the present invention group and the prior art group can reduce the total acidity and pepsin activity of gastric juice (P>0.05).
Figure PCTCN2016073421-appb-000002
Figure PCTCN2016073421-appb-000002
实验3、体内抗菌试验： Experiment 3, in vivo antibacterial test:
本发明组和现有技术组均可以减少金黄色葡萄球菌感染小鼠死亡数,延长感染小鼠的存活天数；Both the present invention group and the prior art group can reduce the number of deaths of S. aureus infected mice and prolong the survival days of infected mice;
实验结果如下：The experimental results are as follows:
组别Group 动物数(只)Number of animals (only) 死亡数(只)Number of deaths (only) 存活率％Survival rate%
正常对照组Normal control group 2020 00 100100
模型组Model group 2020 1212 4040
本发明组Group of the invention 2020 66 7070
现有技术组Existing technology group 2020 99 5555
实验4.抗炎试验结果：Experiment 4. Anti-inflammatory test results:
本发明组和现有技术组均可降低二甲苯所致小鼠耳廓肿胀度。Both the present invention group and the prior art group can reduce the degree of swelling of the auricle caused by xylene in mice.
对小鼠迟发型变态反应(足跖增厚法)影响(足跖厚度差值mm)Effect on delayed type hypersensitivity in mice (ankle thickening method)
剂量组Dose group 动物数(只)Number of animals (only) 注射后24h足跖肿胀度(mm)Swelling degree of foot (24 mm) after injection
阴性对照组Negative control group 1010 0.2140.214
本发明组Group of the invention 1010 0.4640.464
现有技术组Existing technology group 1010 0.3450.345
实验5、加速稳定性实验Experiment 5, accelerated stability experiment
将样品放置在40℃±2℃、相对湿度75％±5％的条件下放置于恒温恒湿箱中，以设定时间取样，对有关成分进行含量测定，试验后的初步稳定性试验结果如下Place the sample in a constant temperature and humidity chamber under the condition of 40 °C ± 2 °C and relative humidity of 75% ± 5%. Sampling at the set time, the content of the relevant components is determined, and the preliminary stability test results after the test are as follows
本发明样品试验后的初步稳定性试验结果Preliminary stability test results after test of the sample of the present invention
Figure PCTCN2016073421-appb-000003
Figure PCTCN2016073421-appb-000003
Figure PCTCN2016073421-appb-000004
Figure PCTCN2016073421-appb-000004
现有技术样品试验后的初步稳定性试验结果Preliminary stability test results after testing of prior art samples
Figure PCTCN2016073421-appb-000005
Figure PCTCN2016073421-appb-000005
本发明的优点主要表现在：The advantages of the present invention are mainly manifested in:
通过改进配方，取得了以下技术效果：降低了药物的服用量，活性成分的含量有所提高，制剂稳定性有所提高，药物的疗效有所提高。By improving the formula, the following technical effects have been achieved: the dosage of the drug is lowered, the content of the active ingredient is increased, the stability of the preparation is improved, and the efficacy of the drug is improved.
具体实施方式：detailed description:
以下通过实施例进一步说明本发明，但不作为对本发明的限制。The invention is further illustrated by the following examples without intending to limit the invention.
实施例1Example 1
配方：formula:
百合60重量份、茯苓60重量份、生地黄65重量份、川芎55重量份、鸡内金15重量份、乌药45重量份、泽泻45重量份、天冬75重量份、三七15重量份、白术30重量份、当归45重量份、茵陈60重量份、地榆75重量份、蒲黄45重量份、延胡索60重量份、白芍150重量份、铁皮石斛75重量份、九节菖蒲45重量份60 parts by weight of lily, 60 parts by weight of glutinous rice, 65 parts by weight of rehmannia glutinosa, 55 parts by weight of Chuanxiong, 15 parts by weight of chicken gold, 45 parts by weight of black peony, 45 parts by weight of Alisma, 75 parts by weight of aspart, and weight of 37. , 30 parts by weight of Atractylodes Rhizome, 45 parts by weight of Angelica sinensis, 60 parts by weight of Yinchen, 75 parts by weight of mantle, 45 parts by weight of Puhuang, 60 parts by weight of Corydalis, 150 parts by weight of Radix, 75 parts by weight of Dendrobium Dendrobium, and 9 45 parts by weight
制备方法：Preparation:
药材加水煎煮2次，每次2小时，合并煎液，滤过，滤液浓缩至适量，加入乙醇，使含醇量达70％，静置，滤过，回收乙醇，滤液浓缩，加水冷藏，滤过，得到药物活性物质，经过制剂方法，制备成药物制剂组合物。The herbs are boiled twice with water for 2 hours, combined with decoction, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content up to 70%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
实施例2Example 2
配方formula
百合30重量份、茯苓30重量份、生地黄40重量份、川芎30重量份、鸡内金5重量份、乌药30重量份、泽泻20重量份、天冬50重量份、三七5重量份、白术10重量份、当归20重量份、茵陈30重量份、 地榆50重量份、蒲黄20重量份、延胡索30重量份、白芍120重量份、铁皮石斛40重量份、九节菖蒲20重量份30 parts by weight of lily, 30 parts by weight of medlar, 40 parts by weight of rehmannia glutinosa, 30 parts by weight of Chuanxiong, 5 parts by weight of chicken gold, 30 parts by weight of peony, 20 parts by weight of Alisma, 50 parts by weight of winter, and 5 parts by weight of Parts, 10 parts by weight of Atractylodes, 20 parts by weight of Angelica, 30 parts by weight of Capillaris, 50 parts by weight of the mantle, 20 parts by weight of Puhuang, 30 parts by weight of Corydalis, 120 parts by weight of peony, 40 parts by weight of Dendrobium candidum, 20 parts by weight of Nine Physalis
制备方法Preparation
药材加水煎煮1次，每次1.5小时，合并煎液，滤过，滤液浓缩至适量，加入乙醇，使含醇量达60％，静置，滤过，回收乙醇，滤液浓缩，加水冷藏，滤过，得到药物活性物质，经过制剂方法，制备成药物制剂组合物。The medicinal materials are boiled for 1 time, 1.5 hours each time, and the decoction is combined, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content 60%, allowed to stand, filtered, and the ethanol is recovered, and the filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
实施例3Example 3
配方formula
百合80重量份、茯苓80重量份、生地黄90重量份、川芎80重量份、鸡内金30重量份、乌药70重量份、泽泻60重量份、天冬90重量份、三七30重量份、白术50重量份、当归60重量份、茵陈80重量份、地榆90重量份、蒲黄60重量份、延胡索80重量份、白芍180重量份、铁皮石斛90重量份、九节菖蒲60重量份80 parts by weight of lily, 80 parts by weight of glutinous rice, 90 parts by weight of rehmannia root, 80 parts by weight of Chuanxiong, 30 parts by weight of chicken gold, 70 parts by weight of black peony, 60 parts by weight of Alisma, 90 parts by weight of winter, and 30 by weight of Parts, Atractylodes 50 parts by weight, Angelica 60 parts by weight, Yinchen 80 parts by weight, 90 parts by weight of mantle, 60 parts by weight of Puhuang, 80 parts by weight of Corydalis, 180 parts by weight of white peony, 90 parts by weight of Dendrobium candidum, and 9 kiln 60 parts by weight
制备方法Preparation
药材加水煎煮3次，每次3小时，合并煎液，滤过，滤液浓缩至适量，加入乙醇，使含醇量达80％，静置，滤过，回收乙醇，滤液浓缩，加水冷藏，滤过，得到药物活性物质，经过制剂方法，制备成药物制剂组合物。The medicinal materials are boiled for 3 times with water for 3 hours, combined with decoction, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content 80%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
实施例4Example 4
胶囊剂的制备Preparation of capsules
取实施例1得到的药物活性物质，经过常规的制剂制备方法，制备成 胶囊剂The pharmaceutically active substance obtained in Example 1 was prepared by a conventional preparation preparation method. Capsule
实施例5Example 5
片剂的制备Preparation of tablets
取实施例1得到的药物活性物质，经过常规的制剂制备方法，制备成片剂The pharmaceutically active substance obtained in Example 1 was prepared into a tablet by a conventional preparation preparation method.
实施例6Example 6
丸剂的制备Preparation of pills
取实施例1得到的药物活性物质，经过常规的制剂制备方法，制备成丸剂Taking the pharmaceutically active substance obtained in Example 1 and preparing a pellet by a conventional preparation preparation method
实施例7Example 7
颗粒剂的制备Preparation of granules
取实施例1得到的药物活性物质，经过常规的制剂制备方法，制备成颗粒剂The pharmaceutically active substance obtained in Example 1 was prepared into a granule by a conventional preparation preparation method.
实施例8Example 8
口服液的制备Preparation of oral liquid
取实施例1得到的药物活性物质，经过常规的制剂制备方法，制备成口服液剂The pharmaceutically active substance obtained in Example 1 was prepared into an oral liquid preparation by a conventional preparation preparation method.
实施例9Example 9
滴丸剂的制备Preparation of pills
取实施例1得到的药物活性物质，经过常规的制剂制备方法，制备成滴丸剂 The pharmaceutically active substance obtained in Example 1 was prepared into a pill by a conventional preparation preparation method.

Claims (7)

  1. 一种治疗胃炎的中药组合物，所述中药组合物由以下重量配比的中药原料药制备而成，A traditional Chinese medicine composition for treating gastritis, the traditional Chinese medicine composition is prepared from the following weight ratio traditional Chinese medicine raw material medicine,
    百合30-80重量份、茯苓30-80重量份、生地黄40-90重量份、川芎30-80重量份、鸡内金5-30重量份、乌药30-70重量份、泽泻20-60重量份、天冬50-90重量份、三七5-30重量份、白术10-50重量份、当归20-60重量份、茵陈30-80重量份、地榆50-90重量份、蒲黄20-60重量份、延胡索30-80重量份、白芍120-180重量份、铁皮石斛40-90重量份、九节菖蒲20-60重量份。Lily 30-80 parts by weight, 茯苓30-80 parts by weight, rehmannia 40-90 parts by weight, Chuanxiong 30-80 parts by weight, chicken inner gold 5-30 parts by weight, black peony 30-70 parts by weight, Alisma 20- 60 parts by weight, 50-90 parts by weight of aspart, 5-30 parts by weight of triplicate, 10-50 parts by weight of Atractylodes, 20-60 parts by weight of Angelica sinensis, 30-80 parts by weight of mersolic, 50-90 parts by weight of mantle, 20-60 parts by weight of Puhuang, 30-80 parts by weight of Corydalis, 120-180 parts by weight of white peony, 40-90 parts by weight of Dendrobium candidum, and 20-60 parts by weight of Nine sylvestris.
  2. 根据权利要求1所述的中药组合物，其特征在于，所述中药组合物由以下重量配比的中药原料药制备而成，The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following weight ratio of traditional Chinese medicine raw materials.
    百合60重量份、茯苓60重量份、生地黄65重量份、川芎55重量份、鸡内金15重量份、乌药45重量份、泽泻45重量份、天冬75重量份、三七15重量份、白术30重量份、当归45重量份、茵陈60重量份、地榆75重量份、蒲黄45重量份、延胡索60重量份、白芍150重量份、铁皮石斛75重量份、九节菖蒲45重量份。60 parts by weight of lily, 60 parts by weight of glutinous rice, 65 parts by weight of rehmannia glutinosa, 55 parts by weight of Chuanxiong, 15 parts by weight of chicken gold, 45 parts by weight of black peony, 45 parts by weight of Alisma, 75 parts by weight of aspart, and weight of 37. , 30 parts by weight of Atractylodes Rhizome, 45 parts by weight of Angelica sinensis, 60 parts by weight of Yinchen, 75 parts by weight of mantle, 45 parts by weight of Puhuang, 60 parts by weight of Corydalis, 150 parts by weight of Radix, 75 parts by weight of Dendrobium Dendrobium, and 9 45 parts by weight.
  3. 权利要求1所述的中药组合物的制备方法，其特征在于，所述制备方法步骤如下：The method for preparing a traditional Chinese medicine composition according to claim 1, wherein the preparation method comprises the following steps:
    药材加水煎煮1-3次，每次1.5-3小时，合并煎液，滤过，滤液浓缩至适量，加入乙醇，使含醇量达60-80％，静置，滤过，回收乙醇， 滤液浓缩，加水冷藏，滤过，得到药物活性物质，经过制剂方法，制备成药物制剂组合物。The medicinal materials are boiled with water for 1-3 times, each time for 1.5-3 hours, and the decoction is combined, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content 60-80%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated, refrigerated by adding water, and filtered to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
  4. 根据权利要求3所述的制备方法，其特征在于，步骤如下：The preparation method according to claim 3, wherein the steps are as follows:
    药材加水煎煮2次，每次2小时，合并煎液，滤过，滤液浓缩至适量，加入乙醇，使含醇量达70％，静置，滤过，回收乙醇，滤液浓缩，加水冷藏，滤过，得到药物活性物质，经过制剂方法，制备成药物制剂组合物。The herbs are boiled twice with water for 2 hours, combined with decoction, filtered, and the filtrate is concentrated to an appropriate amount. Ethanol is added to make the alcohol content up to 70%, allowed to stand, filtered, and the ethanol is recovered. The filtrate is concentrated and refrigerated with water. Filtration is carried out to obtain a pharmaceutically active substance, which is prepared into a pharmaceutical preparation composition by a formulation method.
  5. 根据权利要求1所述的中药组合物，其特征在于，所述中药组合物为任何一种可服用的药物剂型。The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is any pharmaceutical dosage form that can be administered.
  6. 根据权利要求1所述的中药组合物，其特征在于，所述中药组合物为胶囊剂，片剂，丸剂，颗粒剂，口服液，滴丸剂，膏剂。The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition is a capsule, a tablet, a pill, a granule, an oral liquid, a pill, and a paste.
  7. 权利要求1所述的中药组合物在制备具有和胃降逆，健脾消胀，通络定痛之功效，治疗胃炎及胃疼，胀满，痞闷，纳呆，嗳气，烧心等症的药物中的应用。 The traditional Chinese medicine composition according to claim 1 has the effects of preparing stomach-reducing, spleen-swelling, and relieving pain, treating gastritis and stomach pain, fullness, nausea, stagnation, suffocation, heartburn, etc. Application in medicine.
PCT/CN2016/073421 2015-12-30 2016-02-04 Traditional chinese medicine composition for treating gastritis WO2017113475A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201511023069.7 2015-12-30
CN201511023069.7A CN105477375A (en) 2015-12-30 2015-12-30 Traditional Chinese medicine composition for treating gastritis

Publications (1)

Publication Number Publication Date
WO2017113475A1 true WO2017113475A1 (en) 2017-07-06

Family

ID=55664885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/073421 WO2017113475A1 (en) 2015-12-30 2016-02-04 Traditional chinese medicine composition for treating gastritis

Country Status (2)

Country Link
CN (1) CN105477375A (en)
WO (1) WO2017113475A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115944699A (en) * 2022-12-14 2023-04-11 修正药业集团股份有限公司 Traditional Chinese medicine composition with effects of activating spleen, tonifying qi, promoting digestion and removing food stagnation as well as preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1840092A (en) * 2006-01-23 2006-10-04 北京因科瑞斯生物制品研究所 'Mo Luo' granule for treating atrophic gastritis and preparation method thereof
CN103623343A (en) * 2013-11-16 2014-03-12 王纯治 Traditional Chinese medicine mixture for treating eructation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1239187C (en) * 2003-04-17 2006-02-01 邯郸制药有限公司 Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1840092A (en) * 2006-01-23 2006-10-04 北京因科瑞斯生物制品研究所 'Mo Luo' granule for treating atrophic gastritis and preparation method thereof
CN103623343A (en) * 2013-11-16 2014-03-12 王纯治 Traditional Chinese medicine mixture for treating eructation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FENG RUIBING: "Observation on the reversal of atypical Hyperplasia of gastric mucosa in chronic atrophic gastritis by Moluodan Honeyed Pill", CLINICAL MISDIAGNOSIS AND MISTREATMENT, vol. 24, no. 9, 30 September 2011 (2011-09-30), pages 12 - 14 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115944699A (en) * 2022-12-14 2023-04-11 修正药业集团股份有限公司 Traditional Chinese medicine composition with effects of activating spleen, tonifying qi, promoting digestion and removing food stagnation as well as preparation method and application thereof
CN115944699B (en) * 2022-12-14 2024-03-15 修正药业集团股份有限公司 Traditional Chinese medicine composition with effects of activating spleen and tonifying qi, and promoting digestion and resolving stagnation, preparation method and application thereof

Also Published As

Publication number Publication date
CN105477375A (en) 2016-04-13

Similar Documents

Publication Publication Date Title
KR102123972B1 (en) Pharmaceutical composition for treating headache, and preparation method thereof
WO2011113190A1 (en) Pharmaceutical composition for treating aids and preparation method thereof
CN103083557A (en) Traditional Chinese medicine composition with functions of reducing blood pressure and blood fat
WO2010135858A1 (en) Pharmaceutical composition and use for preparing medicament thereof
WO2017113476A1 (en) Traditional chinese medicine composition for treating gastritis
CN102526230B (en) Traditional Chinese composition for curing liver disease and preparation method, quality detection method and application thereof
CN103271978A (en) Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness
WO2017113475A1 (en) Traditional chinese medicine composition for treating gastritis
CN108283687B (en) Medicine and food homologous traditional Chinese medicine composition for preventing and treating hypertension and cardiac injury and application thereof
WO2017101210A1 (en) Gastritis treating traditional chinese medicine composition preparation method and preparation
CN104435045A (en) Traditional Chinese medicine composition for treating stroke and sequela thereof and preparation method thereof
CN111714539B (en) Liver-protecting composition and preparation method and application thereof
CN104435068B (en) A kind of Cortex Eucommiae compositions and preparation thereof with antiobesity action
CN106466396B (en) Gynaecologic menstruation regulating sustained-release dropping pill and preparation method thereof
WO2014090122A1 (en) Pharmaceutical compositions for reducing sugar level, preparation methods and applications thereof
CN109223992A (en) It is a kind of prevent and treat albuminuria Chinese medicine composition and its application
CN103735631B (en) A kind of pharmaceutical composition for the treatment of hepatitis B and preparation method thereof
CN114452369B (en) Traditional Chinese medicine composition for treating breast cancer
WO2014056167A1 (en) Chinese medicinal composition for treating wind-heat common cold and preparation method and application thereof
CN109331097B (en) Stagnation-resolving liver-softening granule and preparation process thereof
CN105456738A (en) Preparation method and preparation of traditional Chinese medicinal composition for treating gastritis
CN105535534A (en) Traditional Chinese medicine composition for treating gastritis
CN105477362A (en) Preparation method of traditional Chinese medicinal composition for treating gastritis and preparation prepared by adopting preparation method
CN106109625B (en) A kind of preparation method of Chinese medicine preparation for heart failure treatment
CN105477360A (en) Preparation method and preparation of traditional Chinese medicinal composition for treating gastritis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16880285

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16880285

Country of ref document: EP

Kind code of ref document: A1